CEO Ajan Reginald discusses Roquefort Therapeutics with Jeremy Naylor at Momentous Events.
“Dr Graham Robertson discussing encouraging Roquefort Therapeutics data on therapeutic antibodies targeting Midkine
Dr Graham Robertson on the advantages of Roquefort Therapeutics’ diverse Midkine portfolio.
Dr Graham Robertson talking about Roquefort Therapeutics’ innovative oligo drug program.
Dr Graham Robertson, Chief Scientific Officer, Australia talks about the presence of Midkine in cancer.